The user's 42 month experience using finasteride for hair loss, their opinion on minoxidil use and the potential of pyrilutamide and another Chinese drug as treatments.
Extended-release oral minoxidil (VDPHL01) shows promising results for hair growth with improved safety, achieving significant hair count increases and minimal side effects compared to placebo. The treatment is designed to maintain effective concentrations while reducing side effects, making it a safer option for those who cannot tolerate standard minoxidil.
The user has been using finasteride, minoxidil, a dermastamp, and red light therapy for six months with no visible improvement since the three-month mark. Other users noted improvement, particularly in the left temple area, and encouraged the user to continue.
New hair loss treatments include Breezula, PP405, ET-02, KX-826, GT20029, VDPHL01, and CosmeRNA, with some showing promise in reactivating stem cells and reversing greying. Breezula and VDPHL01 are highlighted as potential add-ons or alternatives to current treatments like finasteride and minoxidil.
The user continues to experience hair loss despite using dutasteride 2.5mg, minoxidil 5mg, and ciclopirox shampoo, and plans to reassess after one year. Others report similar issues with dutasteride, with some switching to finasteride or adding RU58841.
The conversation is about the use and application of CB-03-01-2 (Breezula) for hair loss, including questions about its form, how to apply it, and the duration 10g would last. Specific treatments discussed are Minoxidil, finasteride, and RU58841.
A 23-year-old male experienced no shedding with RU58841 but switched to oral finasteride due to heart concerns, resulting in increased hair shedding. He is considering adding minoxidil to his regimen, which currently includes finasteride, Nizoral shampoo, and microneedling.
A phase 3 trial for Breezula (clascoterone solution) to treat male pattern hair loss has been listed, with 726 participants and a completion date of January 2025. Other treatments mentioned include Aneira Pharma's combination of minoxidil and latanoprost, Triple Hair's combination of minoxidil, latanoprost, and finasteride, and a new microneedling and LLLT device called StimuSIL.
The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. It also mentions an update on Dr. Bloxham's Verteporfin treatment.
Choosing between two hair loss treatments, with a preference for a higher concentration of RU58841 and 5% minoxidil, avoiding oils like castor and argan that may hinder absorption.
The conversation is about considering switching from Fluridil to Pyrilutamide for hair loss treatment. Pyrilutamide is suggested to be more effective, with a recommendation to use the 1% variant twice daily.
The user reports thicker and fuller hair after using finasteride, topical minoxidil, RU58841, and dermarolling for two years. Consistent lighting is noted as important for progress pictures.
The user experienced concerning side effects like throat irritation, shortness of breath, chest pain, and testicle pain after using RU58841 for hair loss, despite also using finasteride and minoxidil. Other users shared mixed experiences, with one advising to stop using RU58841 due to similar side effects, while another reported significant hair loss reduction without side effects.
The user reported noticeable hair regrowth after using dutasteride 0.5 mg, oral minoxidil 2.5 mg daily, and ketoconazole shampoo weekly for six months. They are considering adding RU58841 for further improvement.
The user is treating hair loss with a regimen including Dutasteride, oral and topical Minoxidil, microneedling, and various supplements for overall health. They are considering adding tretinoin, stemoxydine/RU, DIM, Boron, and Fadogia Agretis to their routine.
The potential stability of pyrilutamide in a mixture with water, and how it could be used in combination with Minoxidil and Finasteride to treat hair loss.
PP405 is a potential hair loss treatment undergoing trials, with discussions on its effectiveness and comparison to existing treatments like finasteride and minoxidil. There is skepticism about its status as a cure, with hopes for future advancements in genetic treatments like CRISPR.
The conversation discusses the effectiveness and side effects of DUT mesotherapy for hair loss. Users are seeking evidence and pictures of successful treatments.
The conversation is about a user considering joining a clinical study for Clascoterone (Breezula) after experiencing no results with topical finasteride and minoxidil, and side effects from oral finasteride. The user is seeking advice on clinical study participation and experiences.
Breezula shows promise in stabilizing hair loss and potentially promoting regrowth at the one-year mark, offering hope for those who can't tolerate 5AR inhibitors. Its local targeting of androgen receptors could be a significant advancement if it avoids systemic side effects.
The conversation is about a user's one-year hair loss treatment using dutasteride, oral and topical minoxidil, ketoconazole, tretinoin, and PRP. Users discuss treatment effectiveness, potential issues with diffuse thinning, and sourcing affordable treatments.
People discuss adding RU58841 to their hair loss treatment, which includes dutasteride and minoxidil. Experiences vary, with some reporting positive results and others experiencing no benefits or side effects.
The user is currently using Minoxidil with melatonin, rosemary, peppermint, azelaic acid, and RU58841 for hair loss and plans to add fluridil and Pyrilutamide. They seek advice on the best Pyrilutamide source, noting Actifolic worked briefly.
A user is seeking a new source for RU58841 in the EU after their previous supplier stopped selling it. They mention considering Anagen, Actifolic, Minoxidilmax, and rudirect, and are using a treatment mixing RU58841 with Stemoxydine and Alfatradiol.
A user is seeking a new source for RU58841 in the EU after their previous supplier stopped selling it. They mention considering Anagen, Actifolic, Minoxidilmax, and rudirect, and are using a treatment mixing RU58841 with Stemoxydine and Alfatradiol.
The conversation is about the potential impact of RU58841 on male fertility, specifically regarding sperm concentration, total count, and motility. The user is curious about the likelihood of RU58841 reducing fertility based on its mechanism of action and comparisons to similar substances.
Breezula's phase 3 results are expected soon, with discussions on the effectiveness of androgen receptor antagonists like spironolactone and the potential of GT20029. Users express skepticism about new treatments and discuss the complexities of male pattern baldness, often relying on finasteride despite its side effects.
The conversation discusses the effectiveness of using 2.5 mg Dutasteride daily versus combining 0.5 mg Dutasteride with 150 mg RU58841 for reducing scalp DHT. Opinions vary, with some users recommending lower doses of Dutasteride and cautioning against RU58841 due to potential side effects.